Weight-Loss Medication Directory
Every medication we cover, grouped by FDA status. 14 entries — ingredient-level records and brand-level records, each linking to official prescribing information.
How to read this directory. FDA approval is specific to an indication — the condition a drug is approved to treat. Two products can share an active ingredient while only one is approved for weight management. Status badges below reflect approval for weight management specifically.
Approved for weight management — active ingredients
Ingredient-level records covering all brands that contain them.
- SemaglutideFDA Approved
- Brand names:
- Wegovy, Ozempic, Rybelsus
- Class:
- GLP-1 receptor agonist
- Administration
- Once weekly (injectable); once daily (oral)
- TirzepatideFDA Approved
- Brand names:
- Zepbound, Mounjaro
- Class:
- Dual GIP and GLP-1 receptor agonist
- Administration
- Once weekly
- LiraglutideFDA Approved
- Brand names:
- Saxenda, Victoza
- Class:
- GLP-1 receptor agonist
- Administration
- Once daily
- OrlistatFDA Approved
- Brand names:
- Xenical, Alli
- Class:
- Lipase inhibitor
- Administration
- Up to three times daily with meals
- PhentermineFDA Approved
- Brand names:
- Adipex-P, Lomaira
- Class:
- Sympathomimetic amine (appetite suppressant)
- Administration
- Typically once daily (see labeling; Lomaira is dosed differently)
- Phentermine-topiramate (extended release)FDA Approved
- Brand names:
- Qsymia
- Class:
- Sympathomimetic amine + antiepileptic (combination)
- Administration
- Once daily
- Naltrexone-bupropion (extended release)FDA Approved
- Brand names:
- Contrave
- Class:
- Opioid antagonist + aminoketone antidepressant (combination)
- Administration
- Twice daily at maintenance (titrated per labeling)
Approved for weight management — brand products
Individual FDA-approved brand products indicated for chronic weight management.
- WegovyFDA Approved
- Active ingredient:
- Semaglutide
- Class:
- GLP-1 receptor agonist
- Administration
- Once weekly
- ZepboundFDA Approved
- Active ingredient:
- Tirzepatide
- Class:
- Dual GIP and GLP-1 receptor agonist
- Administration
- Once weekly
- SaxendaFDA Approved
- Active ingredient:
- Liraglutide
- Class:
- GLP-1 receptor agonist
- Administration
- Once daily
FDA approved for a different indication
These products are FDA approved, but not for weight management. Prescribing them for weight loss is off-label and is generally not covered by insurance.
Investigational — not FDA approved
Compounds in clinical development. They are not approved for any use, cannot legally be dispensed as medication, and have no established safety profile. We do not link to any seller of these compounds.
- RetatrutideInvestigational
- Brand names:
- None (investigational)
- Class:
- Triple GIP, GLP-1, and glucagon receptor agonist
- Administration
- Once weekly (in clinical trials)
- OrforglipronInvestigational
- Brand names:
- None (investigational)
- Class:
- Oral small-molecule GLP-1 receptor agonist
- Administration
- Once daily (in clinical trials)
Not medical advice. WeightLossDrugsGuide is an independent educational publisher. We are not a pharmacy, a medical provider, or a telehealth clinic, and we do not provide personalized medical recommendations or dosing guidance. Information here summarizes official FDA labeling and other primary sources and may not reflect the most recent changes. Always talk with a licensed clinician about your own situation, and read the full prescribing information for any medication.